Colgate Palmolive Co.

CL

NYSE; chemicals; SIC 2844, Perfumes, Cosmetics & Other Toilet Preparations; CIK 0000021665

A

strongest fifth of 329 graded peers in the pooled industrial gr...

rank 40 of 329; percentile 13.7; sampling error 2.7 points; lower is stronger

A B C D E

A, the bull



Scoreboard

Profitability	A percentile 9.8
Solvency	C percentile 53.2
Growth and financing	C percentile 47.6
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $16.3B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	12 of 14
Graded from	filings received through Feb 23, 2026 262 days before the rescan; latest periodic filing 10-Q received Oct 30, 2026
Last close	$97.99 2026-11-11; market equity $77.9B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 23, 2026

Colgate-Palmolive Company (together with its subsidiaries, "we," "us," "our," the "Company" or "Colgate-Palmolive") is a caring, innovative growth company united behind our purpose to reimagine a healthier future for all people, their pets and our planet. To achieve our business and financial objectives and deliver peer-leading performance and total shareholder return, we are focused on driving organic sales growth; delivering consistent, compounded earnings per share growth; achieving operational efficiencies; and driving growth in free cash flow along with the efficient use of our balance sheet.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 9.8						
Gross profitability	75.0%	21.4%		1.7	357	2025-12-31
Return on invested capital	38.4%	9.5%		4.1	124	2025-12-31
Accruals ratio	(12.8%)	(4.2%)		15.4	396	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	1.3 pts	2.2 pts	18.1	299	2025-12-31
Solvency, sleeve percentile 53.2					
Twelve-month failure probability	not computable	0.05%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	6.21	3.42	19.9	298	2025-12-31
Net debt to EBITDA	1.66x	1.86x	44.6	149	2025-12-31
Interest coverage	not computable	4.16x			
one or more required annual facts are missing					
Current ratio	0.83x	2.20x	95.0	421	2025-12-31
Growth and financing, sleeve percentile 47.6					
Revenue growth, three-year compound	4.3%	1.2%	35.2	348	2025-12-31
Free cash flow growth, three-year compound	25.0%	12.5%	31.7	181	2025-12-31
Reinvestment rate	(31.4%)	19.3%	81.0	169	2025-12-31
Asset growth, three years	1.3%	2.8%	59.9	365	2025-12-31
Net share issuance, one year	(1.2%)	0.0%	30.5	316	2026-01-31

Among 329 peers

chemicals; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
35	Axil Brands, Inc. (AXIL)	11.9	A	fortress balance sheet
36	Lincoln Electric Holdings Inc. (LECO)	12.3	A	
37	National Presto Industries Inc. (NPK)	12.6	A	
38	Compx International Inc. (CIX)	13.0	A	fortress balance sheet
39	Weatherford International plc (WFRD)	13.4	A	
40	Colgate Palmolive Co. (CL)	13.7	A	
41	Acme United Corp. (ACU)	13.8	A	
42	Newmarket Corp. (NEU)	14.0	A	
43	Park Aerospace Corp. (PKE)	14.2	A	late filer, fortress balance sheet
44	Innospec Inc. (IOSP)	14.3	A	fortress balance sheet
45	Kadant Inc. (KAI)	14.6	A	

What the price implies

at the 2026-11-11 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	12.8%	10.9%	52
Distance from 52-week high	(1.1%)	(23.0%)	96
EBIT to enterprise value	3.9%	3.7%	51
Free cash flow yield	4.7%	3.3%	66
Book value to price	0.00	0.37	5
Sales to price	0.26	0.55	21
Composite equity issuance, five years	(19.5%)	(10.2%)	24
Relative strength against the sector, log excess return	(0.02)	0.00	46

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$1.5B
Operating cash flow, four quarters	$4.4B
Months of runway	not finite
Days since last periodic filing	13 (10-Q received Oct 30, 2026)
Median daily dollar volume, 63 sessions	$426.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$12.3B	2025-12-31	2026-02-23	10-K	26-000006
2	assets	us-gaap:Assets	$16.3B	2025-12-31	2026-02-23	10-K	26-000006
3	operating income	us-gaap:OperatingIncomeLoss	$3.3B	2025-12-31	2026-02-23	10-K	26-000006
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$3.1B	2025-12-31	2026-02-23	10-K	26-000006
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$798.0M	2025-12-31	2026-02-23	10-K	26-000006
6	total debt	us-gaap:LongTermDebt	$7.8B	2025-12-31	2026-02-23	10-K	26-000006
7	book equity	us-gaap:StockholdersEquity	$54.0M	2025-12-31	2026-02-23	10-K	26-000006
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.3B	2025-12-31	2026-02-23	10-K	26-000006
9	total debt	us-gaap:LongTermDebt	$7.0B	2024-12-31	2025-02-13	10-K	25-000008
10	book equity	us-gaap:StockholdersEquity	$212.0M	2024-12-31	2026-02-23	10-K	26-000006
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.1B	2024-12-31	2026-02-23	10-K	26-000006
12	net income	us-gaap:NetIncomeLoss	$2.1B	2025-12-31	2026-02-23	10-K	26-000006
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$4.2B	2025-12-31	2026-02-23	10-K	26-000006
14	assets	us-gaap:Assets	$16.0B	2024-12-31	2026-02-23	10-K	26-000006
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$20.4B	2025-12-31	2026-02-23	10-K	26-000006
16	gross profit	us-gaap:GrossProfit	$12.2B	2024-12-31	2026-02-23	10-K	26-000006
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$20.1B	2024-12-31	2026-02-23	10-K	26-000006
18	gross profit	us-gaap:GrossProfit	$11.3B	2023-12-31	2026-02-23	10-K	26-000006
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$19.5B	2023-12-31	2026-02-23	10-K	26-000006
20	gross profit	us-gaap:GrossProfit	$10.2B	2022-12-31	2025-02-13	10-K	25-000008
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$18.0B	2022-12-31	2025-02-13	10-K	25-000008
22	gross profit	us-gaap:GrossProfit	$10.4B	2021-12-31	2024-02-15	10-K	24-000003
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$17.4B	2021-12-31	2024-02-15	10-K	24-000003
24	current assets	us-gaap:AssetsCurrent	$5.7B	2025-12-31	2026-02-23	10-K	26-000006
25	current liabilities	us-gaap:LiabilitiesCurrent	$6.9B	2025-12-31	2026-02-23	10-K	26-000006
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$26.6B	2025-12-31	2026-02-23	10-K	26-000006
27	liabilities	us-gaap:Liabilities	$16.0B	2025-12-31	2026-02-23	10-K	26-000006
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$630.0M	2025-12-31	2026-02-23	10-K	26-000006
29	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$564.0M	2025-12-31	2026-02-23	10-K	26-000006
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$4.1B	2024-12-31	2026-02-23	10-K	26-000006
31	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$561.0M	2024-12-31	2026-02-23	10-K	26-000006

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$3.7B	2023-12-31	2026-02-23	10-K	26-000006
33	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$705.0M	2023-12-31	2026-02-23	10-K	26-000006
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.6B	2022-12-31	2025-02-13	10-K	25-000008
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$696.0M	2022-12-31	2023-02-16	10-K	23-000007
36	current assets	us-gaap:AssetsCurrent	$5.3B	2024-12-31	2026-02-23	10-K	26-000006
37	current liabilities	us-gaap:LiabilitiesCurrent	$5.8B	2024-12-31	2026-02-23	10-K	26-000006
38	assets	us-gaap:Assets	$16.4B	2023-12-31	2025-02-13	10-K	25-000008
39	assets	us-gaap:Assets	$15.7B	2022-12-31	2024-02-15	10-K	24-000003
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	801,548,028	2026-01-31	2026-02-23	10-K	26-000006
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	811,536,437	2025-01-31	2025-02-13	10-K	25-000008

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.